Trial Profile

Role of Microbiome In the Realm of Immune-Checkpoint Inhibitor Induced GI Complications In Cancer Population

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 06 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Infliximab (Primary) ; Prednisone (Primary) ; Vedolizumab (Primary)
Indications Chemotherapy-induced damage; Colitis; Diarrhoea
Focus Adverse reactions; Therapeutic Use

Most Recent Events

04 Jun 2024 Results (n=59) presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
06 Jun 2023 Results (n=47) assessing efficacy of efficacy of FMT for refractory Immune-mediated colitis, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
09 Feb 2023 Planned End Date changed from 30 Jan 2023 to 31 Oct 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com